London Daily

Focus on the big picture.
Tuesday, Jul 22, 2025

Breakthrough in treating diseases linked to obesity

Breakthrough in treating diseases linked to obesity

Researchers at two local universities have developed a drug that can treat diseases related to obesity.
The new drug, ABarginase, which can treat prediabetes, type 2 diabetes and nonalcoholic fatty liver disease, recently won the grand prize at the Geneva International Exhibition of Inventions.

Researchers from Polytechnic University and the Chinese University said the drug is a "safe and long-lasting cure to multiple obesity-related diseases."

They said following an eight-week observation that body weight, fatty mass, blood glucose levels and other characteristic features of diabetes in obese mice returned to normal levels after using the drug while on a normal diet.

Alisa Shum Sau-wun, associate professor in School of Biomedical Sciences at CUHK, said: "Currently, some diabetes drugs are very ineffective, others have adverse side effects, such as increasing risk of cancer. There are also diabetes drugs that cause obesity."

And the researchers reported: "Effects were apparent after the first injection. Fatty liver could be entirely reversed after regular use of the drug."

The drug uses arginine starvation, which suppresses fat synthesis, promotes fat breakdown and sensitizes cells to insulin.

They also found there is no drug resistance in a drug that exists naturally in the human body.

Shum said patients need one injection per week for the new drug while older drugs have to be taken two to three times daily.

Thomas Leung Yun-Chung, a Lo Ka Chung Charitable Foundation professor in pharmaceutical sciences at PolyU, said most people would be able to use the drug. He added: "All the test animals got much healthier after taking our drug."

Leung said the belief is that ABarginase should be much cheaper than existing drugs.

There is no drug approved by the US Food and Drug Administration for nonalcoholic fatty liver.

Patent applications have been filed in multiple jurisdictions. Researchers are now scaling up production of ABarginase in preparation for clinical trials.
Newsletter

Related Articles

0:00
0:00
Close
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
×